Cardiovascular Risk Reduction for Adults With Food Insecurity Using Structured Incentives
NCT06818669
Recruiting
The overarching aim of this proposal is to test the efficacy and cost-effectiveness of CVD-FIT, a novel, multi-component intervention that includes three components: 1) monthly income supplementation; 2) weekly structured incentive for the purchase of healthy food options; and 3) evidence-based telephone delivered CVD risk reduction education and skills training in African Americans with food insecurity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University at Buffalo, Buffalo, New York
Conditions: Cardiovascular Diseases
Register for Updates
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Omega Research Consultants, DeBary, Florida +73 locations
Conditions: Arthritis, Psoriatic
Register for Updates
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure: A Randomized Control Trial
NCT06957366
Recruiting
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure involving neuraxial anesthesia. The purpose of the PAUSE 2 study is to show that PAUSE management will be as safe (i.e., non-inferior) as ASRA management, with 95% of patients having low/undetectable pre-operative DOAC levels \<30 ng/mL in each group., at the time of su... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Hartford Health Care, Hartford, Connecticut +13 locations
Conditions: Atrial Fibrillation (AF), VTE
Register for Updates
DBS for Obsessive-Compulsive Disorder
NCT02773082
Recruiting
There are two primary approaches to the treatment of OCD, pharmacotherapy and cognitive behavior therapy (CBT). Lack of therapeutic success with one approach leads to trials of the alternative approach or a combination of the two. A rarely used third therapy approach, appropriate for only the most severely afflicted and treatment resistant patients, is neurosurgical ablation of certain brain regions involved in mood and anxiety. The neurosurgical ablation procedures are irreversible in nature, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Zucker Hillside Hospital, Queens, New York
Conditions: Obsessive-Compulsive Disorder (OCD)
Register for Updates
Pencil Beam Scanning in Patients With Renal Tumors
NCT03810651
Recruiting
This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.
Gender:
ALL
Ages:
Between 0 years and 30 years
Trial Updated:
04/25/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Renal Tumor, Wilms Tumor
Register for Updates
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
NCT04293042
Recruiting
This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.
Gender:
ALL
Ages:
Between 5 weeks and 25 years
Trial Updated:
04/25/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: BK Polyomavirus
Register for Updates
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
NCT04703244
Recruiting
Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Breast Cancer, Residual
Register for Updates
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622
Recruiting
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Neuromuscular Research Center and Clinic, Paradise Valley, Arizona +111 locations
Conditions: Myasthenia Gravis
Register for Updates
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
NCT05172245
Recruiting
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin which is a chemotherapy used in this trial is in a class of medications known as platinum-containing compounds. It works by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Moffitt Cancer Center, Tampa, Florida +17 locations
Conditions: Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Sinonasal Squamous Cell Carcinoma, Maxillary Sinus Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8, Locally Advanced Nasal Cavity Squamous Cell Carcinoma, Locally Advanced Paranasal Sinus Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Register for Updates
A Study of ASP3082 in Adults With Advanced Solid Tumors
NCT05382559
Recruiting
This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: City of Hope National Medical Center, Duarte, California +44 locations
Conditions: Solid Tumor
Register for Updates
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515
Recruiting
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Alaska Oncology and Hematology LLC, Anchorage, Alaska +208 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Striated Esophageal Motor Function Modulation in Health and Disease
NCT05708885
Recruiting
The investigators hypothesize that striated esophagus deglutitive motor function is modulated by pharyngeal phase swallowing biomechanics.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/25/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Dysphagia, Esophageal
Register for Updates